Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CDC25B | P30305 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.64 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.60 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10801712 | 0.94 | KAT8 (0.70) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL2076751 | 0.94 | KAT8 (0.70) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL7018271 | 0.90 | ALDH1A1 (0.68) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL2077145 | 0.87 | PPARA (0.60) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL25170829 | 0.86 | ALDH1A1 (0.78) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL30291197 | 0.86 | ALDH1A1 (0.78) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL1356365 | 0.84 | KAT8 (0.66) | ALDH1A1KAT8PPARAPPARGMETAP2 | |
| SCHEMBL11165456 | 0.83 | SKP2 (0.57) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL12598054 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CDC25BCASP6RCE1KAT8 | |
| SCHEMBL648210 | 0.82 | ALDH1A1 (0.72) | ALDH1A1CDC25BCASP6RCE1KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORPORATION | 2022-11-17 | — | — | US | disclosed |
| EP-3802514-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3802514-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-4745116-A | INHIBITORS OF SERINE PROTEASE | SYNTEX (U.S.A.) INC. (US) | 1988-05-17 | — | — | US | disclosed |
| US-4665070-A | SERINE PROTEINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1987-05-12 | — | — | US | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4642240-A | LOW CALORIE SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0206323-A1 | 2-Oxy-4H-3,1-benzoxazin-4-one derivatives and related compounds | SYNTEX (U.S.A.) INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0015065-B1 | PYRAZOLO (5,1-B) QUINAZOLIN-9(4H)-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1983-12-28 | — | — | EP | disclosed |
| US-4348396-A | Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them | HOFFMANN-LA ROCHE INC. (US) | 1982-09-07 | — | — | US | disclosed |
| US-4261996-A | ANTIHISTAMINES | WARNER-LAMBERT COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0015065-A1 | Pyrazolo (5,1-b) quinazolin-9(4H)-one derivatives, process for their preparation and pharmaceutical compositions containing them | WARNER-LAMBERT COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | ALDH1A1 2219/4885CDC25B 910/4885CASP6 672/4885 |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | LUC7L2, LYPLAL1, GUSB | ALDH1A1 1554/4885CDC25B 3944/4885CASP6 1256/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | ALDH1A1 1554/4885CDC25B 3944/4885CASP6 1256/4885 |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | ALDH1A1 1554/4885CDC25B 3944/4885CASP6 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.